Skip to main content
PolicySpeak
← All files
DNV

DNV

Company · Norway · EU Transparency Register 414057515145-62

4
positions filed
in the 665 files tracked
3
legislative files
of 665 tracked
3
with a full position paper
attached to a submission

Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.

Who they are

Among the 1210 companies & groups on this site, they rank #442 by legislative files engaged, a count of participation, not a measure of influence.

2
declared lobbying FTE
self-declared
€200K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2014
in the register since

Declares membership of

Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).

Register category
Companies & groups
Head office
Høvik, Norway

Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.

Track DNV in PolicySpeak: request access →

Follow DNV

An email when this organization files on a consultation we publish.

We use your email for these updates, and PolicySpeak may contact you about the product. Unsubscribe in one click. Privacy policy.

Work at DNV? so we know who speaks for it.

Their record over time

DNV filed 4 positions between 8 Jun 2026 and 12 Oct 2026, across 3 of the 665 legislative files tracked here, attaching a full position paper 3 times.

What they argued

Simplifying and reducing the burden of the rules on medical devices and in vitro diagnostic medical devices, and support of the European Medicines Agency for the expert panels on medical devices and the list of Union harmonisation legislationfiled 8 Jun 2026PDFsource

DNV's full contribution is attached, and summarized hereafter. DNV welcomes the European Commissions effort to revisit Regulation (EU) 2017/745 (MDR) in order to improve implementation, reduce avoidable burden and support timely access to safe and effective medical devices and in vitro diagnostics in the European Union.

EU Emissions Trading System and market stability reserve: competitiveness and cost-effective decarbonisationfiled 12 Oct 2026PDFsource

DNV COMMENTS ON THE EU ETS AND MRV REVIEW DNV welcomes the review and proposed updates to the ETS Directive and MRV Regulation. DNV strongly supports the stronger investment orientation of the proposal. The planned Industrial Decarbonisation Bank, with €100 billion in funding, the ETS Investment Booster estimated at €30 billion, the continuation of the Innovation Fund and the requirement that Member States spend 50%…

Opening of the attached position paper · the full paper is on the Commission’s record (source link above)

EU Emissions Trading System and market stability reserve: competitiveness and cost-effective decarbonisationfiled 12 Oct 2026PDFsource

DNV COMMENTS ON THE EU ETS AND MRV REVIEW DNV welcomes the review and proposed updates to the ETS Directive and MRV Regulation. DNV strongly supports the stronger investment orientation of the proposal. The planned Industrial Decarbonisation Bank, with €100 billion in funding, the ETS Investment Booster estimated at €30 billion, the continuation of the Innovation Fund and the requirement that Member States spend 50%…

Opening of the attached position paper · the full paper is on the Commission’s record (source link above)

Carbon price paid in a third country under the carbon border adjustment mechanism (CBAM)filed 10 Jun 2026source

DNV welcomes the opportunity to provide input on the draft implementing regulation concerning the recognition of carbon prices paid in third countries under the Carbon Border Adjustment Mechanism (CBAM). The proposal represents an important step towards ensuring that carbon costs borne outside the EU are appropriately accounted for, while maintaining the environmental integrity of CBAM.

Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.

Put DNV next to another organization. Same files, same register facts, side by side. Compare →

Turns up on the same files

Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.

Showing 5 of 35.

Is this your organization?

Everything on this page comes from DNV’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.

Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.